½ÃÀ庸°í¼­
»óǰÄÚµå
1702369

¼¼°èÀÇ Ç³¼±ÆÇ¸·¼ºÇü¼ú ±â±â ½ÃÀå(2025-2033³â)

Global Balloon Valvuloplasty Devices Market - 2025-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: DataM Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® 165 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Àü ¼¼°è dz¼±ÆÇ¸·¼ºÇü¼ú ±â±â ½ÃÀå ±Ô¸ð´Â 2024³â 20¾ï 3,000¸¸ ´Þ·¯¿¡¼­ 2033³â¿¡´Â 39¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ̸ç, ¿¹Ãø ±â°£ÀÎ 2025-2033³â¿¡´Â 6.8%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

dz¼±ÆÇ¸·¼ºÇü¼ú ±â±â´Â ½ÉÀåÆÇ¸·ÀÇ ÇùÂøÀ» Ä¡·áÇÏ´Â µ¥ »ç¿ëµÇ´Â ÀÇ·á±â±âÀÔ´Ï´Ù. ÆÇ¸· ÀÔ±¸¸¦ ³ÐÇô Ç÷·ù¸¦ °³¼±Çϰí Áõ»óÀ» ¿ÏÈ­ÇÕ´Ï´Ù. Áõ»ó ¿ÏÈ­, ȸº¹ ½Ã°£ ´ÜÃà, ÀÔ¿ø ±â°£ ´ÜÃàÀ» ¸ñÀûÀ¸·Î ÁßÀçÀû ½ÉÀ庴Çп¡¼­ ÀϹÝÀûÀ¸·Î »ç¿ëµË´Ï´Ù.

¼¼°è dz¼±ÆÇ¸·¼ºÇü¼ú ±â±â ½ÃÀåÀº ´ëµ¿¸ÆÆÇ¸· ÇùÂøÁõ, ½Â¸ðÆÇ¸· ÇùÂøÁõ, Æóµ¿¸ÆÆÇ Áúȯ°ú °°Àº ½ÉÀåÆÇ¸· ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Àα¸ °í·ÉÈ­¿Í °íÇ÷¾Ð, ´ç´¢º´, ºñ¸¸, Èí¿¬°ú °°Àº »ýȰ½À°ü °ü·Ã À§Çè¿äÀÎÀº ÀÌ·¯ÇÑ ÁúȯÀ» ´õ¿í ¾ÇÈ­½Ã۰í ÀÖ½À´Ï´Ù. dz¼±ÆÇ¸· ¼ºÇü¼úÀº ¼ö¼úÀû ÆÇ¸· ġȯ¼úÀ» ´ëüÇÒ ¼ö ÀÖ´Â ÃÖ¼Òħ½ÀÀû Ä¡·á¹ýÀ¸·Î, ÀÔ¿ø ±â°£ ´ÜÃà, ȸº¹ ½Ã°£ ´ÜÃà, ¼ö¼ú ÈÄ ÇÕº´Áõ °¨¼Ò µîÀÇ ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù.

¿¹¸¦ µé¾î, ½ÉÇ÷°ü°è ÁúȯÀÎ ½ÉÀåÆÇ¸·ÁõÀº Àü ¼¼°èÀûÀ¸·Î Áõ°¡Çϰí ÀÖÀ¸¸ç, ±× Áß 4,100¸¸ ¸íÀÌ ¾Î°í ÀÖ´Â ·ù¸¶Æ¼½º¼º ½ÉÀåÁúȯÀº °³¹ßµµ»ó±¹¿¡¼­ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ÀþÀº ¼ºÀÎ Àα¸ÀÇ Áõ°¡¿Í Ç×»ýÁ¦, ¹Ì»ý¹°ÇÐÀû °Ë»ç, ½ÉÃÊÀ½ÆÄ °Ë»ç¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ °³¼±µÇ¾î Á¶±â »ç¸Á·üÀÌ ³·¾ÆÁ³±â ¶§¹®ÀÔ´Ï´Ù.

¼¼°è dz¼±ÆÇ¸·¼ºÇü¼ú ½ÃÀåÀº ÀçÇùÂø ¹× ±âŸ ½Ã¼ú ÇÕº´ÁõÀ¸·Î ÀÎÇÑ µµÀü¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÀçÇùÂøÀº ½Ã¼ú ÈÄ Ä¡·áµÈ ÆÇ¸·ÀÌ ´Ù½Ã Á¼¾ÆÁö´Â °ÍÀ» ÀǹÌÇϸç, ÀÌ´Â Á¾Á¾ Àç¼ö¼úÀ» ÇÊ¿ä·Î Çϰí ȯÀÚ¿Í ÀÇ·á ½Ã½ºÅÛ¿¡ ºÎ´ãÀ» ÁÖ°Ô µË´Ï´Ù. À̴ ƯÈ÷ °í·ÉÀÇ È¯ÀÚ³ª ¼®È¸È­°¡ ½ÉÇØ ½Ã¼ú È¿°ú°¡ ÀϽÃÀûÀÏ ¼ö Àִ ȯÀÚ¿¡¼­ µÎµå·¯Áö°Ô ³ªÅ¸³³´Ï´Ù.

´Ù¸¥ À§ÇèÀ¸·Î´Â Ç÷°ü ÇÕº´Áõ, »öÀüÁõ, ºÎÁ¤¸Æ, ÆÇ¸· ¿ª·ù µîÀÌ ÀÖÀ¸¸ç, À̴ ȯÀÚÀÇ ¿¹Èĸ¦ ¾ÇÈ­½Ãų ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÇÕº´ÁõÀÇ °¡´É¼ºÀ¸·Î ÀÎÇØ ÀÇ·áÁøÀº ƯÈ÷ ¼ö¼úÀû ÆÇ¸· ġȯ¼ú°ú °°Àº ´õ ¿À·¡ Áö¼ÓµÇ´Â ´ëü Ä¡·á¹ýÀÌ ÀÖ´Â °æ¿ì, ÀÌ ½Ã¼úÀÇ ±¤¹üÀ§ÇÑ Ã¤ÅÃÀ» ÁÖÀúÇϰí ÀÖ½À´Ï´Ù. °æÇÇÀû ´ëµ¿¸Æ ÆÇ¸· ġȯ¼ú(TAVR)°ú °°Àº ´ëü Ä¡·á ¿É¼ÇÀÌ ÀÖ´Ù´Â Á¡µµ dz¼±ÆÇ¸·¼ºÇü¼ú ½ÃÀåÀÇ ¼ºÀåÀ» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù.

¼¼°èÀÇ Ç³¼±ÆÇ¸·¼ºÇü¼ú ±â±â ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä¿Í ÇÔ²² Á¦Ç° À¯Çüº°, ¿ëµµº°, ¿¬·Éº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° µ¿Çâ, °æÀï ±¸µµ, ½ÃÀå ÁøÃâ ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ½ÃÀå ¼Ò°³¿Í ¹üÀ§

Á¦2Àå °æ¿µÀÚ ÀλçÀÌÆ®¿Í Áß¿äÇÑ Æ÷ÀÎÆ®

Á¦3Àå ½ÃÀå ¿ªÇÐ

  • ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • ¿µÇ⠺м®

Á¦4Àå Àü·«Àû ÀλçÀÌÆ®¿Í ¾÷°è Àü¸Á

  • ½ÃÀå ¸®´õ¿Í ÆÄÀÌ¿À´Ï¾î
  • CXOÀÇ °ßÇØ
  • Ãֽа³¹ß°ú Çõ½Å
  • »ç·Ê ¿¬±¸/ÁøÇàÁßÀÎ Á¶»ç
  • ±ÔÁ¦¿Í »óȯ »óȲ
  • Porter's Five Forces ºÐ¼®
  • °ø±Þ¸Á ºÐ¼®
  • ƯÇ㠺м®
  • SWOT ºÐ¼®
  • ¹ÌÃæÁ· ¼ö¿ä¿Í °ÝÂ÷
  • ½ÃÀå ÁøÃâ ¹× È®ÀåÀ» À§ÇÑ Ãßõ Àü·«
  • ½Ã³ª¸®¿À ºÐ¼® : º£½ºÆ® ÄÉÀ̽º, ±âº» ÄÉÀ̽º, ¿ö½ºÆ® ÄÉÀ̽º ¿¹Ãø
  • °¡°Ý ºÐ¼®°ú °¡°Ý µ¿Çâ
  • KOL(Key Opinion Leader)

Á¦5Àå Á¦Ç° À¯Çüº°

  • Ç¥ÁØ Ç³¼±
  • Ä¿ÆÃ dz¼±
  • ½ºÄھ dz¼±
  • °í¾Ð dz¼±
  • Àú¾Ð dz¼±

Á¦6Àå ¿ëµµº°

  • ´ëµ¿¸ÆÆÇÇùÂøÁõ
  • Æóµ¿¸ÆÆÇÇùÂøÁõ

Á¦7Àå ¿¬·ÉÃþº°

  • ¼Ò¾Æ
  • ¼ºÀÎ

Á¦8Àå ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • Àü¹® Ŭ¸®´Ð
  • ±âŸ

Á¦9Àå Áö¿ª ½ÃÀå ºÐ¼®°ú ¼ºÀå ±âȸ

  • ºÏ¹Ì
    • Áö¿ª ƯÀ¯ÀÇ ÁÖ¿ä µ¿Çâ
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ
  • À¯·´
    • Áö¿ª ƯÀ¯ÀÇ ÁÖ¿ä µ¿Çâ
      • µ¶ÀÏ
      • ¿µ±¹
      • ÇÁ¶û½º
      • ½ºÆäÀÎ
      • ÀÌÅ»¸®¾Æ
      • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • Áö¿ª ƯÀ¯ÀÇ ÁÖ¿ä µ¿Çâ
      • ºê¶óÁú
      • ¾Æ¸£ÇîÆ¼³ª
      • ±âŸ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áö¿ª ƯÀ¯ÀÇ ÁÖ¿ä µ¿Çâ
      • Áß±¹
      • Àεµ
      • ÀϺ»
      • Çѱ¹
      • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áö¿ª ƯÀ¯ÀÇ ÁÖ¿ä µ¿Çâ

Á¦10Àå °æÀï ±¸µµ¿Í ½ÃÀå Æ÷Áö¼Å´×

  • °æÀï »óȲ °³¿ä¿Í ÁÖ¿ä ½ÃÀå ÁøÀÔ ±â¾÷
  • ½ÃÀå Á¡À¯À² ºÐ¼®°ú Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·«Àû ÆÄÆ®³Ê½Ê, ÀμöÇÕº´
  • Á¦Ç° Æ÷Æ®Æú¸®¿À¿Í Çõ½ÅÀÇ ÁÖ¿ä ¹ßÀü
  • ±â¾÷ º¥Ä¡¸¶Å©

Á¦11Àå ±â¾÷ °³¿ä

  • Medtronic
    • ±â¾÷ °³¿ä
    • Á¦Ç° Æ÷Æ®Æú¸®¿À
    • À繫 °³¿ä
    • ÁÖ¿ä ¹ßÀü
    • SWOT ºÐ¼®
  • Balton
  • Boston Scientific Corporation
  • B. Braun Melsungen AG
  • Cardinal Health, Inc
  • Cook Medical Inc
  • Terumo Corporation
  • Becton, Dickinson and Company(BD)
  • TORAY MEDICAL CO,. LTD.
  • BVM Medical

Á¦12Àå °¡Á¤°ú Á¶»ç ¹æ¹ý

Á¦13Àå ºÎ·Ï

ksm 25.04.22

The global balloon valvuloplasty devices market reached US$ 2.03 billion in 2024 and is expected to reach US$ 3.95 billion by 2033, growing at a CAGR of 6.8% during the forecast period 2025-2033.

Balloon valvuloplasty devices are medical devices used to treat valvular stenosis, a narrowing of heart valves. They widen the valve opening, improve blood flow, and reduce symptoms. They're commonly used in interventional cardiology for symptom relief, shorter recovery times, and reduced hospitalization duration.

Market Dynamics: Drivers & Restraints

Rising Prevalence of Valvular Heart Diseases

The global balloon valvuloplasty devices market is driven by the increasing prevalence of valvular heart diseases, such as aortic stenosis, mitral stenosis, and pulmonary valve disorders. The aging population and lifestyle-related risk factors like hypertension, diabetes, obesity, and smoking further exacerbate these conditions. Balloon valvuloplasty is a minimally invasive alternative to surgical valve replacement, offering benefits like shorter hospital stays, faster recovery times, and reduced post-operative complications.

For instance, valvular heart disease, a global cardiovascular disease, is increasing globally, with rheumatic heart disease, the most common, affecting 41 million people, increasing in developing nations. This is due to the growth of the young adult population and improved access to antibiotics, microbiological testing, and echocardiography, which have reduced premature mortality rates.

Risk of Restenosis and Procedural Complications

The global balloon valvuloplasty devices market faces challenges due to restenosis and other procedural complications. Restenosis, the re-narrowing of the treated valve after the procedure, often requires repeat interventions, burdening patients and healthcare systems. This is particularly evident in elderly patients or those with severe calcification, where the procedure's effectiveness may be temporary.

Other risks include vascular complications, embolization, arrhythmias, and valve regurgitation, leading to adverse patient outcomes. The potential for complications makes healthcare providers hesitant to adopt the procedure widely, especially when more durable alternatives like surgical valve replacement are available. The availability of alternative treatment options, such as transcatheter aortic valve replacement (TAVR), may also limit the growth of the balloon valvuloplasty devices market.

Segment Analysis

The global balloon valvuloplasty devices market is segmented based on product type, application, age group, end user, and region.

Product Type:

The standard balloon from product type segment is expected to dominate the balloon valvuloplasty devices market with the highest market share

Standard balloons are medical devices used in balloon valvuloplasty to dilate narrowed heart valves, restoring blood flow in patients with valvular stenosis. These high-strength balloons, available in various sizes and diameters, are delivered via catheter-based systems and inflated to break calcific deposits, improving valve function in high-risk patients not candidates for open-heart surgery.

The balloon valvuloplasty devices market is growing due to the increasing prevalence of valvular heart diseases, preference for minimally invasive procedures, technological advancements, expanding healthcare infrastructure, and government initiatives. Benefits include reduced hospital stays, faster recovery times, and fewer post-operative complications. Technological advancements and improved access to interventional cardiology in developing regions further support market growth.

Geographical Analysis

North America is expected to hold a significant position in the balloon valvuloplasty devices market with the highest market share

The North American balloon valvuloplasty devices market is growing due to the increasing prevalence of valvular heart diseases, especially among the aging population. Technological advancements and favorable reimbursement policies are driving innovation. Increased awareness among healthcare professionals and patients, coupled with rising healthcare expenditure and government support for cardiovascular disease management, is expected to further accelerate market growth in North America.

For instance, in January 2025, Concept Medical has enrolled the first patient in its MAGICAL trial, comparing its sirolimus-coated balloon to traditional angioplasty for patients with below-the-knee PDA. The company secured an Investigational Device Exemption from the FDA for the MagicTouch PTA and is launching two more trials to evaluate its drug-coated alternative.

Competitive Landscape

The major global players in the balloon valvuloplasty devices market include Medtronic, Balton, Boston Scientific Corporation, B. Braun Melsungen AG, Cardinal Health, Inc., Cook Medical Inc., Terumo Corporation, Becton, Dickinson and Company (BD), TORAY MEDICAL CO,.LTD., and BVM Medical, among others.

Key Developments

  • In February 2025, Cagent Vascular launched the Serranator SL-PRO percutaneous transluminal angioplasty (PTA) serration balloon catheter for chronic limb-threatening ischaemia and pedal disease. The catheter uses Cagent's proven serration technology on a redesigned platform, offering improved deliverability and trackability. It also offers 1,000 times increase in point force compared to plain balloons and a controlled lumen gain with minimal dissection.

Why Purchase the Report?

  • Technological Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global balloon valvuloplasty devices market report delivers a detailed analysis with 70 key tables, more than 74 visually impactful figures and 165 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Application & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by Age Group
  • 2.6. Snippet by End User
  • 2.7. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Prevalence of Valvular Heart Diseases
      • 3.1.1.2. Rise in the Technological Advancements
    • 3.1.2. Restraints
      • 3.1.2.1. Risk of Restenosis and Procedural Complications
      • 3.1.2.2. High Cost of Devices
    • 3.1.3. Opportunity
      • 3.1.3.1. Expansion in Emerging Markets
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Force Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Standard Balloon*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Cutting Balloon
  • 5.4. Scoring Balloon
  • 5.5. High-Pressure Balloon
  • 5.6. Low-Pressure Balloon

6. By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Aortic Valve Stenosis*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Pulmonary Valve Stenosis

7. By Age Group

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 7.1.2. Market Attractiveness Index, By Age Group
  • 7.2. Pediatric*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Adult

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Ambulatory Surgical Centers
  • 8.4. Specialty Clinics
  • 8.5. Others

9. Regional Market Analysis and Growth Opportunities

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.7.1. U.S.
      • 9.2.7.2. Canada
      • 9.2.7.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.7.1. Germany
      • 9.3.7.2. U.K.
      • 9.3.7.3. France
      • 9.3.7.4. Spain
      • 9.3.7.5. Italy
      • 9.3.7.6. Rest of Europe
  • 9.4. Latin America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.7.1. Brazil
      • 9.4.7.2. Argentina
      • 9.4.7.3. Rest of Latin America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.7.1. China
      • 9.5.7.2. India
      • 9.5.7.3. Japan
      • 9.5.7.4. South Korea
      • 9.5.7.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
  • 10.2. Market Share Analysis and Positioning Matrix
  • 10.3. Strategic Partnerships, Mergers & Acquisitions
  • 10.4. Key Developments in Product Portfolios and Innovations
  • 10.5. Company Benchmarking

11. Company Profiles

  • 11.1. Medtronic*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio
      • 11.1.2.1. Product Description
      • 11.1.2.2. Product Key Performance Indicators (KPIs)
      • 11.1.2.3. Historic and Forecasted Product Sales
      • 11.1.2.4. Product Sales Volume
    • 11.1.3. Financial Overview
      • 11.1.3.1. Company Revenue
      • 11.1.3.2. Geographical Revenue Shares
      • 11.1.3.3. Revenue Forecasts
    • 11.1.4. Key Developments
      • 11.1.4.1. Mergers & Acquisitions
      • 11.1.4.2. Key Product Development Activities
      • 11.1.4.3. Regulatory Approvals, etc.
    • 11.1.5. SWOT Analysis
  • 11.2. Balton
  • 11.3. Boston Scientific Corporation
  • 11.4. B. Braun Melsungen AG
  • 11.5. Cardinal Health, Inc
  • 11.6. Cook Medical Inc
  • 11.7. Terumo Corporation
  • 11.8. Becton, Dickinson and Company (BD)
  • 11.9. TORAY MEDICAL CO,. LTD.
  • 11.10. BVM Medical

LIST NOT EXHAUSTIVE

12. Assumption and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦